Home・Lista de Ações・TransMedics Group Inc

TransMedics Group Inc

Fechado

SetorSaúde

80.5 -1.38

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

78.31

Máximo

81.92

Indicadores-chave
By Trading Economics
Rendimento	-98M 7.3M
Vendas	13M 174M
P/E Médio do Setor	16.998 64.641
EPS	0.3
Margem de lucro	4.206
Funcionários	898
EBITDA	-4.9M 28M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+41.02% upside

Dividendos
By Acuity
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-786M 2.6B
Abertura anterior	81.88
Fecho anterior	80.5

Sentimento de Notícias

By Acuity

65%

35%

289 / 340 Ranking em Healthcare

TransMedics Group Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de ago. de 2026, 19:51 UTC

Social Media

News

TransMedics Group Inc. shares are rising, despite an analyst downgrade to a $106 price target from $142, amid positive social media discussions.

30 de jul. de 2026, 19:03 UTC

Transmedics Group Inc shares are lower during Thursday's session, with no specific news identified. Broader market uncertainty may be influencing the decline.

29 de jul. de 2026, 23:36 UTC

Transmedics Group Inc. shares are lower in after-market trading, reflecting broader market volatility amid rising interest rates and geopolitical tensions.

28 de jul. de 2026, 19:46 UTC

Transmedics Group Inc shares are higher today, advancing since Monday. The stock peaked earlier but pulled back from a session high.

27 de jul. de 2026, 15:16 UTC

Social Media

News

Transmedics Group Inc is higher today amid social media discussions on its undervaluation and expectations for significant profit by 2028.

24 de jul. de 2026, 20:02 UTC

Social Media

Transmedics Group Inc gains amid positive feedback from Jefferies on its technology and growth prospects, aligning with strength in the Health Care Equipment sector.

22 de jul. de 2026, 19:46 UTC

Transmedics Group Inc shares are lower today, reflecting ongoing declines. The stock's volatility coincides with rising crude oil prices amid geopolitical tensions.

21 de jul. de 2026, 14:36 UTC

Social Media

Transmedics Group's shares are higher today following the first lung transplant using its OCS warm-perfusion device, enhancing organ preservation and clinical outcomes.

20 de jul. de 2026, 12:26 UTC

Social Media

TransMedics Group Inc shares are higher in pre-market trading amid strong operational growth, with flights exceeding 36 per day and projected revenue of $3 billion by 2032.

Comparação entre Pares

Variação de preço

TransMedics Group Inc Previsão

Preço-alvo

By TipRanks

41.02% parte superior

Previsão para 12 meses

Média 115 USD 41.02%

Máximo 175 USD

Mínimo 80 USD

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para TransMedics Group Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

10 ratings

Comprar

Manter

Vender

Com base em 10 analistas que deram avaliações de ações para TransMedics Group Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

289 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.